- Home
- OBE vs KRRO Comparison
OBE vs KRRO Comparison
Compare OBE & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- KRRO
- Stock Information
- Founded
- OBE 1979
- KRRO 2014
- Country
- OBE Canada
- KRRO United States
- Employees
- OBE N/A
- KRRO N/A
- Industry
- OBE Oil & Gas Production
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- OBE Energy
- KRRO Health Care
- Exchange
- OBE Nasdaq
- KRRO Nasdaq
- Market Cap
- OBE 377.1M
- KRRO 358.3M
- IPO Year
- OBE N/A
- KRRO 2019
- Fundamental
- Price
- OBE $5.88
- KRRO $34.30
- Analyst Decision
- OBE Hold
- KRRO Strong Buy
- Analyst Count
- OBE 1
- KRRO 8
- Target Price
- OBE $9.00
- KRRO $96.25
- AVG Volume (30 Days)
- OBE 354.8K
- KRRO 194.0K
- Earning Date
- OBE 10-30-2025
- KRRO 11-12-2025
- Dividend Yield
- OBE N/A
- KRRO N/A
- EPS Growth
- OBE N/A
- KRRO N/A
- EPS
- OBE N/A
- KRRO N/A
- Revenue
- OBE $441,312,666.00
- KRRO $6,281,000.00
- Revenue This Year
- OBE N/A
- KRRO $116.91
- Revenue Next Year
- OBE N/A
- KRRO N/A
- P/E Ratio
- OBE N/A
- KRRO N/A
- Revenue Growth
- OBE N/A
- KRRO N/A
- 52 Week Low
- OBE $3.88
- KRRO $10.29
- 52 Week High
- OBE $7.07
- KRRO $76.79
- Technical
- Relative Strength Index (RSI)
- OBE 47.64
- KRRO 42.32
- Support Level
- OBE $5.47
- KRRO $31.17
- Resistance Level
- OBE $6.13
- KRRO $42.70
- Average True Range (ATR)
- OBE 0.26
- KRRO 3.80
- MACD
- OBE -0.00
- KRRO -1.37
- Stochastic Oscillator
- OBE 52.47
- KRRO 20.10
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.